Cancer markers for screening: what you need to know before a «preventive checkup»

Tumor marker screening is often seen as a quick way to make sure everything is okay. The idea that a single blood test can «detect cancer early» is appealing. However, modern medicine looks at this issue much deeper.

Screening — it’s not just testing. It’s a system for early detection of disease in people without symptoms. For a test to be suitable for mass screening, it must be as accurate as possible, have a low percentage of false-positive results, and actually reduce mortality from the disease. Most tumor markers do not meet these criteria.

Why the idea of a "blood test for cancer" seems logical, but doesn't always work

Tumor markers are substances that can be produced by tumor cells or tissues in the body in response to a pathological process. However, they are not unique to malignant tumors.

Their level may increase with:

• chronic inflammation

• benign neoplasms

• infections

• hormonal changes

• age-related characteristics

• the influence of smoking or other lifestyle factors

That is why a result above the norm does not automatically mean an oncological process.

According to recommendations World Health Organization, effective screening should be based on methods with proven benefits for the population, not just on laboratory indicators.

Main problem: low specificity

For screening, it is important that the test clearly distinguishes patients from healthy individuals. Most tumor markers have limited specificity.

This means:

• possible false positive results

• unnecessary examinations

• unnecessary invasive procedures

• psychological stress

Specialists Mayo Clinic emphasize that tumor markers are much more effective for monitoring an already established diagnosis than for the initial search for a tumor.

When tumor markers can still be part of a screening strategy

There are situations where cancer marker testing is used in narrow risk groups. But even then, it is not used in isolation.

In each case, the decision is made individually.

Screening and monitoring: two different goals

Screening is the search for a disease in people without symptoms.
Monitoring is the control of the condition after diagnosis or in a high-risk group.

Tumor markers are most informative for:

• evaluation of the effectiveness of therapy

• early detection of relapse

• progression control

In such cases, changes in dynamics are more important than absolute numbers.

Why «giving all tumor markers for prevention» does not increase safety

Preventive testing without an indication may create the illusion of control, but does not guarantee early detection of cancer. A normal result does not exclude the disease, and a moderate increase often turns out to be non-oncological.

According to the position FDA, laboratory tests should be used only when they affect further clinical tactics.

What really works in early detection of oncology

Evidence-based screening programs include:

• mammography

• cytological studies

• colonoscopy

• low-dose CT for risk groups

These methods have proven efficacy in reducing mortality. Tumor markers can complement them in certain clinical situations, but not replace them.

Who should discuss cancer marker testing with a doctor?

Consultation is advisable if:

• there is a family history of cancer

• there are warning symptoms

• the patient belongs to a risk group

• necessary follow-up after treatment

In such cases, tumor markers become part of a well-thought-out diagnostic plan.

Tumor markers for screening: a balanced and personalized approach

Tumor markers for screening are not a universal tool for early detection of cancer in a healthy person. Their role is limited and clearly defined by clinical guidelines. Rational use of tests, assessment of individual risks, and consultation with a doctor are key elements of modern preventive medicine.

A balanced approach avoids unnecessary examinations and at the same time not to miss the really important changes.